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Abstract
Seven new [acronyculatins I–O (1–7)] and four known acetophenone monomers were isolated 
from a CH3OH/CH2Cl2 (1:1) extract (N089419) of Acronychia trifoliolata provided by the U.S. 
National Cancer Institute (NCI, Frederick, MD, USA). Their structures were characterized by 
using various NMR and HRMS techniques. Among the known compounds, the structure of 
acronyculatin B (8) was revised. Some of the isolated compounds were evaluated for 
antiproliferative activity against human cancer cell lines. While most of the tested compounds 
were not cytotoxic, acronyculatins I (1) and J (2) showed moderate antiproliferative activity.
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The genus Acronychia (Rutaceae) contains about 48 species1 of small trees or shrubs found 
in tropical regions of China, Southeast Asia, India, Australia, and islands of the Pacific 
Ocean. Many species have been used in traditional folk medicines for the treatment of 
diarrhea, cough, asthma, sores, ulcers, itchy skin, scales, pain, and rheumatism.2,3 
Phytochemical and pharmacological studies on almost half of these species have revealed 
the presence of flavonoids, cinnamic acids, lignans, coumarins, steroids, and triterpenoids as 
secondary metabolites.2 The most distinctive metabolites of Acronychia are prenylated 
acetophenones3–10 and furoquinoline alkaloids.10–12
Acronychia trifoliolata Zoll. & Moritzi is distributed from Java and Christmas Island to the 
Solomon Islands and is locally called “batjaena alae” in Sulawesi, Indonesia, and “kaya 
djerouk” in Australia.2 A literature search showed a single report on this species. It 
described the isolation of three acetophenone dimers as well as their cytotoxic activities.7 In 
the course of studies focused on the discovery of bioactive natural products with new 
structures from rainforest plants, A. trifoliolata was selected for further investigation. A 
CH3OH/CH2Cl2 (1:1) extract of A. trifoliolata (N089419), provided by the U.S. National 
Cancer Institute (NCI, Frederick, MD, USA), exhibited potent antiproliferative activity 
against several human tumor cell lines. Because the NCI had no more material available, the 
project was started using the limited amount (4.9 g) of extract. Herein the isolation and 
structure elucidation of 12 secondary metabolites, including seven new acetophenone 
monomers, are described.
RESULTS AND DISCUSSION
Analysis of the crude organic extract of A. trifoliolata in the NCI-60 human tumor cell assay 
indicated that the extract was broadly cytotoxic, inhibiting the growth of 50% of tested 
cancer cells at a mean concentration of 0.3 μg/mL and killing those cells at a mean 
concentration of 1.7 μg/mL (Figure S1, Supporting Information). On the basis of this initial 
activity, the extract was selected for identification of its bioactive chemical constituents.
The 50% CH3OH/CH2Cl2 extract of the bark of A. trifoliolata (4.9 g) was fractionated with 
EtOAc and water to provide EtOAc- and water-soluble fractions. The EtOAc-soluble 
fraction was separated by a combination of MPLC, silica gel column chromatography, and 
preparative thin-layer chromatography (TLC) techniques to give seven new acetophenone 
monomers, acronyculatins I–O (1–7), together with the known acronycu-latin B (8),3 
acronyculatin E (9),3 acronyculatin G (10),5 1-[2′,4′-dihydroxy-6′-methoxy-3′,5′-di(3″-
methyl-2″-butenyl)]-phenylethanone (11),13 and acronylin (12)14 as shown in Figure 1.
Compound 1 showed a protonated molecular ion at m/z 335.1845 in the HRFABMS, 
corresponding to the molecular formula C19H26O5. The IR absorption bands at 3442, 2978, 
and 1616 cm−1 indicated hydroxy, hydrogen-bonded hydroxy, and carbonyl groups, 
respectively. The 1H NMR data of 1 (Table 1) showed signals assignable to an olefinic (δH 
5.22), an oxymethine (δH 3.83), two methylenes [δH 3.29 (2H, d, J = 7.2 Hz), 2.97 (1H, dd, J 
= 16.8, 5.2 Hz), and 2.72 (1H, dd, J = 16.8, 6.4 Hz)], a methoxy (δH 3.75), an acetyl (δH 
2.68), four methyls (δH 1.79, 1.67, 1.374, and 1.365), and a hydrogen-bonded hydroxy 
proton (δH 13.25). The 13C NMR data of 1 (Table 1) revealed 19 signals, including those of 
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a ketocarbonyl (δC 203.3), a pair of olefinic carbons (δC 131.4 and 122.2), six aromatic 
carbons (δC 161.1, 159.7, 157.4, 113.2, 109.3, and 104.3), an oxygenated tertiary carbon (δC 
77.8), and an oxymethine (δC 69.2). These data resembled those of the known acronyculatin 
G (10),5 which was also isolated in this study, except for the C-1″ benzylic methylene and 
C-2″ oxymethine in 1 instead of an olefinic moiety in 10. The 2D NMR experiments, 
including H–H COSY, HMQC, and HMBC, revealed the presence of a benzene moiety fully 
substituted with an acetyl, a hydroxy, a prenyl, a methoxy, and a 2,3-dioxygenated 2-
methylbutane moiety (Figure 2). The latter moiety was likely a 2,2-dimethyl-3,4-
dihydro-2H-pyran ring system, as suggested by the molecular formula of 1. On the basis of 
several observations, the dihydropyran ring was fused to the benzene at C-4′ and C-5′, 
while the prenyl group was attached at C-3′. These assignments, as well as those of the 
acetyl, hydroxy, and methoxy groups, were supported by the NOE correlations observed 
between the C-1″ dihydropyran methylene protons and the C-6′ methoxy protons and 
between the C-1‴ methylene protons and the C-2′ hydroxy proton. Second, the phenolic 
proton showed intramolecular hydrogen bonding with the carbonyl oxygen of the acetyl 
group. Thus, the structure of 1 was concluded to be 1-[3,7-dihydroxy-5-methoxy-2,2-
dimethyl-8-(3-methylbut-2-en-1-yl)chroman-6-yl]ethan-1-one, a hydrated derivative of 10.5 
It was given the trivial name acronyculatin I following the related acetophenone monomers 
acronyculatins A–H3,5 from Acronychia species.
The 1H NMR spectrum of 2 was similar to that of 1. However, the olefinic signal in 1 was 
absent, while aliphatic signals were observed at δH 1.55 (2H, m) and 1.35 (1H, m). The 
protonated molecular ion peak of 2 was observed at m/z 337.2012, indicative of two 
additional hydrogens in the structure of 2 versus 1. On the basis of these data, compound 2 
contains a hydrogenated prenyl group compared with 1 and was fully characterized as 1-
(3,7-dihydroxy-8-isopentyl-5-methoxy-2,2-dimethylchroman-6-yl)-ethan-1-one and named 
acronyculatin J.
Compound 3 showed a protonated molecular ion at m/z 335.1850 in the HRFABMS, 
corresponding to the same molecular formula, C19H26O5, as 1. The 1H NMR data (Table 1) 
of 3 were closely comparable to those of the known acronyculatin E (9),3 which was co-
isolated in this study, except for benzylic methylene (δH 2.90, 2.69) and oxymethine (δH 
3.84) signals in 3 compared with two olefinic proton peaks in 9. Collectively, these 
observations implied the presence of a dihydropyran in 3 rather than the pyran in 9. A 
hydrogen-bonded phenolic proton (δH 13.60) suggested that this ring was attached at C-3′ 
and C-4′ of the benzene moiety. The NOESY correlations observed between the prenyl 
benzylic methylene protons at C-1‴ (δH 3.26) and the methoxy protons (δH 3.72) 
established that the prenyl group in 3 was attached to C-5′ on the benzene moiety. Thus, 
compound 3, acronyculatin K, was characterized as 1-[3,5-dihydroxy-7-methoxy-2,2-
dimethyl-8-(3-methylbut-2-en-1-yl)chroman-6-yl]ethan-1-one.
The 1H NMR data of 4 (Table 1) resembled those of 3, except for the presence of a non-
hydrogen-bonded phenolic proton (δH 5.74) in 4 instead of a hydrogen-bonded proton (δH 
13.60) in 3. On the basis of the NOESY correlations of the prenyl benzylic methylene 
signals at δH 3.35 (2H, brd, J = 7.2 Hz) with those of methoxy and phenolic protons at δH 
3.71 (3H, s) and δH 5.74 (1H, s), respectively, the prenyl group in 4 was located at C-5′ of 
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the chromane moiety. In addition, HRFABMS data of compound 4 showed the molecular 
formula C19H26O5, which suggested the presence of a dihydropyran ring in the structure. As 
the phenolic proton (δH 5.74) did not show any hydrogen bonding, the dihydropyran ring 
was linked at the benzene C-2′ and C-3′ positions. Compound 4, acronyculatin L, was, 
therefore, identified as 1-[3,5-dihydroxy-7-methoxy-2,2-dimethyl-6-(3-methylbut-2-en-1-
yl)chroman-8-yl]ethan-1-one. Compounds 3 and 4 are regioisomers, differing in the 
positions of the dihydropyran and phenolic group, i.e., C3′/C4′ and C-2′ versus C2′/C3′ 
C-4′, respectively.
The 1H NMR data of 5 (Table 1) revealed the presence of an acetyl group (δH 2.62, 3H, s), a 
hydrogen-bonded phenolic proton (δH 14.00, 1H, s), a methoxy moiety (δH 3.91, 3H, s), and 
a prenyl group (olefinic proton at δH 5.24, 1H, brt, J = 6.6 Hz; methylene at δH 3.26, 2H, d, J 
= 6.6 Hz; gem-dimethyls at δH 1.76 and 1.67, each 3H, brs, respectively), which were 
similar to those of 1. However, signals for a methylene (δH 3.46, 1H, dd, J = 16.2, 6.0 Hz, 
and δH 3.16, 1H, dd, J = 16.2, 2.4 Hz), a hydroxy (δH 3.18, 1H, d, J = 4.8 Hz), and 
hemiacetal (δH 6.14, 1H, ddd, J = 6.4, 4.8, 2.4 Hz) protons were observed for 5 instead of 
those for a dihydropyran moiety in 1. The HMBC cross-peaks of the methylene and 
hemiacetal protons with C-4′ (δC 162.9) supported the presence of a dihydrofuran ring. On 
the basis of the NOESY spectrum that showed a correlation between the hydrogen-bonded 
phenolic proton and the prenyl methylene group, the prenyl group was located at C-3′. 
Accordingly, the structure of 5, acronyculatin M, was concluded to be 1-[2,6-dihydroxy-4-
methoxy-7-(3-methylbut-2-en-1-yl)-2,3-dihydro-benzofuran-5-yl]ethan-1-one.
According to HRFABMS analysis, the molecular weight of 6 is C11H12O5, which implied 
the loss of a five-carbon unit from 5. This assumption was confirmed by the 1H NMR 
spectrum of 6, in which the proton signals related to a prenyl group were clearly absent, 
while an aromatic proton (δH 6.17, 1H, s) was present. A NOESY correlation between the 
methoxy protons (δH 3.96, 3H, s) and benzylic methylene (δH 3.17, 1H, dd, J = 15.6, 2.4 Hz 
and 3.46, 1H, dd, J = 15.6, 6.0 Hz) on the dihydrofuran moiety suggested that 6, 
acronyculatin N, is a deprenylated derivative of 5.
Compounds 1–6 displayed small specific rotation values as shown in the Supporting 
Information. Compound 1 was esterified using Mosher’s reagent in an attempt to define the 
C-2″ absolute configuration. Although the specific rotation of 1 was slightly negative 
([α]21D –2.7, c 0.1, CH3OH), the resulting Mosher esters existed as a 1:1 mixture of 
diastereomers based on the 1H NMR observation, as shown in Figure 3. Therefore, the 
specific resolution value could be considered within the range of error. The extremely small 
isolated quantities of the remaining new compounds were insuficient for further 
investigation. However, it is highly possible that compounds 2–6 could also be racemates, 
because their biosynthesis pathways would presumably proceed similarly.
Compound 7 showed a protonated molecular ion at m/z 335.1845 in the HRFABMS, 
corresponding to the molecular formula C19H26O5. The 1H and 13C NMR spectra of 7 were 
closely similar to those of known acronyculatin B (8),3 also isolated in this study. They 
differed only in the spin patterns of the benzylic methylene on the dihydrofuran ring (δH 
3.14 and 3.04 for 7; δH 3.26 for 8) and the hydrogen-bonded hydroxy proton (δH 13.30 for 
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7; δH 14.52 for 8). The 2D NMR experiments revealed that the benzene moiety of 7 was 
fully substituted with acetyl, hydroxy, methoxy, prenyl, and dihydrofuran groups. A NOESY 
experiment revealed correlations between the methoxy protons and the acetyl methyl protons 
at δH 2.67 (3H, s) as well as the prenyl benzylic methylene protons at δH 3.25 (2H, brd, J = 
6.4 Hz). On the basis of these data, the structure of 7 would be assigned as identical to that 
of 8, which was reported previously.3 However, in CDCl3, the two benzylic (prenyl and 
dihydrofuran) signals of 8 (δH 3.26 and 3.22) were overlapped and could not be 
distinguished. In contrast, in acetone-d6 (Supporting Information), the corresponding signals 
were resolved. Furthermore, from a NOESY experiment, the dihydrofuran benzylic 
methylene protons (δH 3.36) were correlated with the methoxy protons (δH 4.00). These new 
data indicated that the hydroxy and the methoxy groups in the reported structure of 
acronyculatin B (8) should be reversed.15 It should be noted that acronyculatin B isolated 
from A. trifoliolata was a racemate, while an optically active compound was isolated from 
A. pedunculata.3
The antiproliferative activity of selected acetophenone monomers, 1–4, 7, and 8, was 
evaluated. Acetophenones 1 and 2 exhibited IC50 values around 20 μM, while the four 
remaining acetophenones showed IC50 values in excess of 40 μM against several human 
tumor cell lines, as shown in Table 2. These results indicated that a pyran moiety is favored 
relative to a furan ring for antiproliferative activity (1 vs 8). The location of substituents 
could also affect the activity. For example, a hydroxy group positioned to participate in 
hydrogen bonding to a neighboring carbonyl group was important for activity (1 vs 4).
Eleven acetophenone monomers, including seven new compounds were isolated from the 
rainforest plant A. trifoliolata Zoll. & Moritzi. Their chemical structures were characterized 
from NMR, HRMS, and IR spectroscopic data. Information regarding the total syntheses 
and additional biological evaluation of the compounds will be reported elsewhere.16
EXPERIMENTAL SECTION
General Experimental Procedures
Optical rotations were recorded on a JASCO P-2200 digital polarimeter. Infrared spectra 
(IR) were measured with a Shimadzu FTIR-8700 instrument for samples in CHCl3. NMR 
spectra were recorded on JEOL JMN-ECA600 and JMN-ECS400 spectrometers with 
tetramethylsilane as an internal standard, and chemical shifts are expressed as δ values. 
HRMS data were obtained on a JMS-SX102A (FAB) or JMS-T100TD (DART) mass 
spectrometer. Analytical and preparative TLC were carried out on precoated silica gel 
60F254 and RP-18F254 plates (0.25 or 0.50 mm thickness; Merck). MPLC was performed 
with silica gel and C18 cartridges (Biotage, Uppsala Sweden).
Plant Material
The bark of A. trifoliolata was collected in Bali, Indonesia, at an altitude of 1200 m on July 
5, 1994, by Dr. Djaja D. Soejarto and identified by taxonomist A. McDonald. A voucher 
specimen (#U44Z-4773) is housed at the Smithsonian Institution, Washington, DC, and a 
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voucher extract (N089419) was deposited at the NCI and Kanazawa University (Kanazawa, 
Japan).
NCI-60 Cell Cytotoxicity Assay
Analysis of the cytotoxicity of the crude organic extract of A. trifoliolata was achieved by 
testing in vitro a 60-cell tumor screening panel of the NCI as reported previously.17 Briefly, 
a single 100 μg/mL concentration of organic extract N089419 was tested against 60 human 
cancer cell lines. Upon initial indication of activity in the single-dose experiment, the extract 
was subsequently tested at five doses starting at 100 μg/mL and decreasing by logarithmic 
dilution to a final concentration of 0.01 μg/mL. Cell viability after 48 h of incubation was 
visualized using sulforhodamine B as reported previously.17
Extraction and Isolation
A CH3OH/CH2Cl2 (1:1) extract of the bark of A. trifoliolata (4.9 g) was dissolved in H2O 
and partitioned with EtOAc to yield EtOAc-soluble (3.8 g) and H2O-soluble fractions. The 
H2O-soluble fraction was subjected to Diaion HP-20 column chromatography with 
CH3OH/H2O (0, 30, 50, 70, and 100%) to yield five fractions. The EtOAc-soluble fraction 
(3.7 g) was dissolved into EtOAc, the precipitate was removed, and the EtOAc-soluble 
portion was subjected to silica gel MPLC (KP-Sil 100 g) with a CH3OH/CHCl3 gradient 
system [0:1 (5 fractions) → 2:98 (5 fractions) → 10:90 (5 fractions) → 1:0 (1 fraction); 
collection per 100 mL] to yield 16 fractions.
Fraction 2 (750 mg) was subjected to silica gel MPLC (SNAP HP-Sil 25 g) with EtOAc/n-
hexane [1:19, 12 column volumes (CVs) and 1:4, 5 CVs] followed by CH3OH to yield 18 
subfractions. Subfraction 4 (50.6 mg) was purified by preparative TLC with toluene/n-
hexane (1:1), reversed-phase MPLC (KP-C18-HS 12 g) with 60% acetone/H2O, and 
preparative TLC with EtOAc/toluene (1:9) to yield acronyculatin O (7, 1.4 mg), 1-[2′,4′-
dihydroxy-6′-methoxy-3′,5′-di(3″-methyl-2″-butenyl)]phenylethanone (11, 9.5 mg), and 
acronyculatins E (9, 0.8 mg), L (4, 0.5 mg), and G (10, 0.4 mg).
Fraction 3 (150 mg) was subjected to silica gel MPLC (SNAP Ultra 10 g) with CHCl3 (15 
CVs) followed by CH3OH to yield 16 subfractions. Subfraction 3 (63.7 mg) was purified by 
MPLC on silica gel (SNAP Ultra 10 g) with EtOAc/n-hexane (1:19, 15 CVs) and EtOAc, 
followed by reversed-phase preparative TLC with CH3OH/H2O/HOAc (90:9:1), to afford 
acronyculatins K (3, 0.6 mg) and B (8, 0.6 mg).
Fraction 4 (155 mg) was subjected to MPLC on silica gel (Zip Sphere 5 g) with a 
CH3OH/CH2Cl2 gradient system [0:1 (6 fractions) → 1:99 (4 fractions) → 2:98 (3 
fractions) → 5:95 (2 fractions); collection per 10 mL] to yield 15 subfractions. Subfraction 
7 (2.4 mg) was combined with subfraction 3 of fraction 5 (16.3 mg), then purified by 
normal-phase preparative TLC with EtOAc/n-hexane (3:7) and EtOAc/toluene (1:4) or 
reversed-phase preparative TLC with CH3CN/H2O (4:1), to afford acronyculatins M (5, 0.8 
mg) and N (6, 0.3 mg) and acronylin (12, 0.6 mg).
Fraction 5 (290 mg) was subjected to MPLC on silica gel (Zip Sphere 10 g) with a 
CH3OH/CH2Cl2 gradient system [0:1 (6 CVs) → 1:99 (6 CVs) → 2:98 (6 CVs) → 10:90 
Miyake et al. Page 6
J Nat Prod. Author manuscript; available in PMC 2017 November 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
(1 CV)] to yield 19 subfractions. Subfraction 4 (153 mg) was further purified by reversed-
phase MPLC (KP-C18-HS 12 g) with CH3OH/H2O (9:1, 6 CVs), then CH3OH (5 CVs), 
followed by reversed-phase preparative TLC with CH3CN/H2O/HOAc (80:19:1) and 
normal-phase preparative TLC with acetone/toluene (9:1) and EtOAc/n-hexane (2:3), to 
yield acronyculatins I (1, 1.2 mg) and J (2, 0.3 mg).
Acronyculatin I (1): colorless, amorphous solid; IR νmax (CHCl3) cm−1 3442, 2978, 2928, 
1616, 1592, 1444, 1366, 1291; 1H and 13C NMR, Table 1; FABMS m/z 335, 279; 
HRFABMS m/z 335.1845 [M + H]+ (calcd for C19H27O5, 335.1858).
Acronyculatin J (2): colorless, amorphous solid; IR νmax (CHCl3) cm−1 3443, 2952, 2953, 
1615, 1433, 1365, 1279; 1H NMR, Table 1; FABMS m/z 337; HRFABMS m/z 337.2012 [M 
+ H]+ (calcd for C19H29O5, 337.2015).
Acronyculatin K (3): colorless, amorphous solid; IR νmax (CHCl3) cm−1 3443, 2923, 1613, 
1415, 1366, 1268; 1H NMR, Table 1; FABMS m/z 335; HRFABMS m/z 335.1850 [M + H]+ 
(calcd for C19H27O5, 335.1858).
Acronyculatin L (4): colorless, amorphous solid; IR νmax (CHCl3) cm−1 3435, 2925, 1686, 
1595, 1421, 1367; 1H NMR, Table 1; FABMS m/z 335, 279; HRFABMS m/z 335.1828 [M 
+ H]+ (calcd for C19H27O5, 335.1858).
Acronyculatin M (5): colorless, amorphous solid; IR νmax (CHCl3) cm−1 3353, 2923, 1614, 
1416, 1370; 1H and 13C NMR, Table 1; FABMS m/z 293, 237, HRFABMS m/z 293.1392 
[M + H]+ (calcd for C16H21O5, 293.1389).
Acronyculatin N (6): colorless, amorphous solid; IR νmax (CHCl3) cm−1 3445, 2918, 2359, 
1620, 1421, 1366; 1H NMR, Table 1; FABMS m/z 225; HRFABMS m/z 225.0764 [M + H]+ 
(calcd for C11H13O5, 225.0764).
Acronyculatin O (7): colorless, amorphous solid; IR νmax (CHCl3) cm−1 3453, 2929, 1614, 
1423, 1366; 1H and 13C NMR, Table 1; FABMS m/z 335; HRFABMS m/z 335.1845 [M + 
H]+ (calcd for C19H27O5, 335.1858).
Acronyculatin B (8): colorless, amorphous solid; IR νmax (CHCl3) cm−1 3434, 2919, 1615, 
1367; FABMS m/z 335; HRFABMS m/z 335.1814 [M + H]+ (calcd for C19H27O5, 
335.1858).
Esterification of Compound 1 with (S)-MTPACl
To a solution of 1 (0.6 mg, 0.002 mmol) in anhydrous CH2Cl2 (0.2 mL) were added Et3N 
(1.0 μL, 0.007 mmol), 4-dimethylaminopyridine (DMAP) (0.6 mg, 0.005 mmol), and (S)-
MTPACl (1.0 μL, 0.005 mmol) at rt. After stirring for 21 h, Et3N (2.0 μL, 0.014 mmol), 
DMAP (1.3 mg, 0.01 mmol), and (S)-MTPACl (2.0 μL, 0.01 mmol) were added to the 
mixture, and stirring continued for 6 h. The mixture was purified using preparative TLC 
with EtOAc/n-hexane (1:2) to afford the MTPA ester (0.6 mg, 61%) as a 1:1 diastereomeric 
mixture.
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Mosher ester of 1: 1H NMR (400 MHz, CDCl3) δ 13.2 and 13.2 (1H, s, 7-OH, 1:1), 5.19–
5.14 [1H, m, 8-CH2CH=C(CH3)2], 5.19–5.14 (1H, m, 3-H), 3.65 and 3.64 (3H, s, 5-OCH3, 
1:1), 3.27 and 3.25 [2H, d, J = 4.8 Hz, 8-CH2CH=C(CH3)2, 1:1], 3.07 and 3.05 (1H, dd, J = 
6.8, 3.2 Hz, 4-H, 1:1), 2.92 and 2.76 (1H, dd, J = 11.2, 3.6 Hz, 4-H, 1:1), 2.67 and 2.66 (3H, 
s, 6-Ac, 1:1), 1.76 and 1.73 [3H, s, 8-CH2CH=C(CH3)2, 1:1], 1.65 and 1.61 [3H, s, 8-
CH2CH=C(CH3)2, 1:1], 1.36 and 1.33 [3H, s, 2-(CH3)2, 1:1], 1.32 and 1.30 [3H, s, 2-
(CH3)2, 1:1].
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Structures of compounds 1–12 isolated from A. trifoliolata.
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Figure 2. 
Selected HMBC correlations (arrows), COSY connectivities (bold lines), and NOESY 
correlations (dotted arrows) for 1–8.
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Figure 3. 
MTPA ester of 1 and 1H NMR spectrum.
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